ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial
avril 2, 2007
PDF 68,0 KB
DownloadInnovative treatments that address unmet medical needs in neurological and related central nervous system disorders.
ACADIA Pharmaceuticals is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders.
Sale of listed shares in 2010.
Human Health
Industry
Biotech
Status
Realised
Location
US